Optimal timing of remdesivir initiation in hospitalized COVID-19 patients administered with dexamethasone.

Carlos King-Ho WongKristy T K LauIvan C H AuXi XiongMatthew S H ChungEric H Y LauBenjamin J Cowling

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)

Initiation of remdesivir prior to or simultaneously with dexamethasone was associated with significantly shorter time to clinical improvement and positive IgG antibody, lower risk of in-hospital death, in addition to shorter length of hospital stay in patients with moderate COVID-19.

Keyphrases

sars cov
coronavirus disease
high dose
healthcare
low dose
acute care
adverse drug
high intensity
emergency department
respiratory syndrome coronavirus